COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid — is less clear. Research ...

Dr. Astha Muttreja, a physician at the Stony Brook Medicine's post-COVID Clinic in Lake Grove, said there had been “cautious optimism” that Paxlovid would be a potential treatment method for ...

Paxlovid isn't the only antiviral medication for COVID-19. Merck’s Lagevrio is another available pill, though it's proven to be less popular in the U.S. than Paxlovid.

Paxlovid, impacting its distribution and use in treating mild-to-moderate COVID-19. In December 2021, the FDA authorized Paxlovid for emergency use for the treatment of adults and pediatric ...

When Paxlovid was first authorized for emergency use in the U.S. in December 2021, it was free for anyone who needed it. Once the government stopped funding the treatment, Pfizer set a list price ...

Pfizer won't say. A Harvard study last year estimated the cost of producing generic Paxlovid at about $15 per treatment course, including manufacturing expenses, a 10% profit markup, and 27% in taxes.

Paxlovid is the most commonly prescribed at home treatment for COVID-19 in the U.S. It is approved to treat COVID in adults who are at risk of severe complications from the illness.

Paxlovid, available since December 2021, reduced the COVID-19 death rate in high-risk patients by 73%, according to a study National Institutes of Health researchers released last year.

Study: The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19. Image Credit: Tobias Arhelger/Shutterstock.com Background ...